FDA-Approved Peptides: The Full List (2026)

Which Peptides Are FDA-Approved?

More peptides are FDA-approved than most people realize, and fewer of the famous ones than most people assume. Insulin is a peptide. So are oxytocin, glucagon, and desmopressin, all of them approved prescription drugs that have been in pharmacies for decades. The newest generation is the GLP-1 class: semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are peptide drugs that went through full FDA review and now rank among the most prescribed medications in the country.

Then there is the other group, the peptides that dominate search results and podcast episodes. BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , TB-500, CJC-1295/Ipamorelin Explore PeRxCJC-1295/IpamorelinPulsatile Growth Hormone ReleaseView peptide , Epitalon Explore PeRxEpitalonThe Longevity PeptideView peptide , MOTS-C Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide , DSIP Explore PeRxDSIPDeep Sleep PeptideView peptide . None of these is FDA-approved, and none has ever completed the clinical trial program approval requires. They occupy a different lane entirely: compounded medications, prepared by licensed pharmacies for individual patients under a prescription from a licensed provider. That lane is real and regulated, but it is not approval, and any site that blurs the two is misleading you.

Approved vs Compounded vs Research: The Three Lanes

Almost every confused headline about peptides comes from collapsing three separate categories into one. Keeping them apart makes the whole landscape legible.

Lane one: FDA-approved drugs. An approved drug has completed the full New Drug Application process: preclinical work, Phase 1 through Phase 3 human trials, FDA review of the data, and approval for a specific indication. The manufacturer can market it, insurers can cover it, and the FDA inspects its production. Ozempic is in this lane. So is Forteo. This is the highest evidentiary bar in American medicine, and it typically costs hundreds of millions of dollars to clear.

Lane two: compounded medications. Federal law has always allowed licensed pharmacies to prepare medications for individual patients under a prescription. A 503A compounding pharmacy operates under state pharmacy boards and federal compounding law. The medication it prepares is not FDA-approved, because approval attaches to a specific manufactured product, not a molecule. This is the lane where BPC-157, Sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide , CJC-1295/Ipamorelin, and the other therapy peptides live, and it is also where compounded versions of semaglutide and tirzepatide come from. Prescription required, licensed pharmacy required, but no FDA review of the product itself.

Lane three: research chemicals. Websites selling peptides "for research purposes only" with no prescription, no pharmacy, and no provider sit outside both regulated lanes. No one verifies what is in the vial, purity testing is whatever the seller claims, and the "research only" label is a legal fig leaf, since the products are plainly sold for human use. Independent analyses of gray-market peptides have repeatedly found dosing inaccuracies and contamination. This lane is the reason the FDA talks about peptide safety at all, and it is the lane every legitimate provider tells you to avoid.

One more distinction worth pinning down: "not FDA-approved" does not mean "banned" or "illegal." Compounding is a recognized part of federal pharmacy law, and everyday medications from hormone preparations to pediatric dosage adjustments move through it constantly. For the dated, step-by-step history of how the FDA has treated compounded peptides specifically, our FDA peptide review timeline tracks every action with sources.

The Full List of FDA-Approved Peptide Drugs

Here are the notable peptide drugs the FDA has approved, with brand names, indications, and approval years. Chemists draw the peptide-versus-protein line at roughly 40 amino acids, so this list sticks to true peptides; larger biologics like growth hormone are a separate category.

A few entries deserve a closer look, because their stories explain how the whole peptide landscape got its shape.

Insulin is where peptide medicine began. It was first given to a patient in 1922, decades before the modern FDA approval framework existed. The 1982 approval of Humulin made it the first recombinant DNA drug ever cleared in the United States, and the FDA reviewed it in five months at a time when the average was over two years. Every peptide drug since has walked a path insulin opened.

The GLP-1 class is the modern era. Liraglutide arrived first as Victoza in 2010 and gained a weight-management approval as Saxenda in 2014. Semaglutide followed with three separate approvals: Ozempic for type 2 diabetes in 2017, Rybelsus as the first oral GLP-1 tablet in 2019, and Wegovy for chronic weight management in 2021. Tirzepatide, which activates the GIP receptor alongside GLP-1, was approved as Mounjaro in 2022 and Zepbound in 2023. These approvals are the reason "peptide" stopped being a niche word.

Bremelanotide is PT-141 Explore PeRxPT-141On-Demand Intimacy EnhancementView peptide with an NDA. The molecule known in compounding as PT-141 was approved by the FDA in June 2019 as Vyleesi, an on-demand injection for hypoactive sexual desire disorder in premenopausal women. It is the clearest example of a compounded-era peptide finishing the full approval journey. The full story, including how the compounded and branded versions relate, is in our guide to PT-141's FDA status Read nextIs PT-141 FDA Approved? Yes, As VyleesiThis one is complicated. The molecule in PT-141 (bremelanotide) is FDA-approved as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women. But the compounded version used in peptide therapy is prescribed off-label for broader sexual health applications in both men and women. Same molecule, different regulatory paths.Read article .

Tesamorelin is the growth-hormone-axis success story. Approved as Egrifta in 2010 to reduce excess abdominal fat in HIV-associated lipodystrophy, it proved that a growth hormone releasing hormone analog could clear Phase 3 trials, with 816 patients across two randomized studies. It is the closest FDA-approved relative of compounded peptides like CJC-1295/Ipamorelin Read nextIs CJC-1295/Ipamorelin FDA Approved? (2026 Answer)The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.Read article , which work on the same axis but never entered the approval pipeline.

Sermorelin is the strange one. The FDA approved it in 1997 as Geref for pediatric growth hormone deficiency. In 2008 the manufacturer discontinued it, and the FDA later determined in a published Federal Register notice that the withdrawal was not for safety or effectiveness reasons. The molecule did nothing wrong; the market moved. Today Sermorelin exists only as a compounded medication, which gives it the most unusual regulatory resume in the compounded lane: a peptide with a completed, successful FDA approval behind it. Sermorelin's full approval history Read nextIs Sermorelin FDA Approved? Yes Until 2008Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.Read article covers the whole arc.

The 2026 Compounding Review

The list above is the approval lane. The biggest regulatory story of 2026, though, is happening in the compounding lane, and it is worth understanding precisely because so much coverage gets it wrong.

In 2023 the FDA placed a group of popular compounded peptides, including BPC-157 and TB-500, in its restricted Category 2, effectively signaling that pharmacies should not compound them. In April 2026 the agency reversed course and removed twelve peptides from that restricted list. That removal did not approve anything and did not add the peptides to the 503A bulks list of substances formally cleared for compounding. It left them in a gray zone: no longer restricted, not yet listed, and not FDA-approved. Gray zone, not a ban, is the accurate framing, however the headlines put it.

Then came the July 23-24, 2026 meeting of the FDA's Pharmacy Compounding Advisory Committee, which reviewed seven of those peptides for formal addition to the compounding list. The committee recommended six: BPC-157, KPV, TB-500, MOTS-C, Semax Explore PeRxSemax/SelankCognitive Clarity & Calm FocusView peptide , and Epitalon. It declined to recommend one, Emideltide, better known as DSIP, in a narrow 6-7 vote. Notably, every one of the six recommendations went against the FDA's own staff briefing documents, which had proposed adding none. Our full breakdown of the FDA panel votes Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article covers every tally and what happens next.

If you want the per-peptide detail, we keep a dedicated status guide for each: BPC-157 Read nextIs BPC-157 FDA Approved in 2026? The Honest AnswerNo. BPC-157 has never been submitted for FDA approval and has never entered formal clinical trials. It is available as a compounded medication prescribed by licensed providers. Despite being the most widely used peptide in therapy, its entire evidence base comes from preclinical research. Here is what that means and why millions of people use it anyway.Read article , TB-500 Read nextIs TB-500 FDA Approved? Parent in Phase 2 TrialsNo. TB-500 is not FDA-approved. But its parent molecule, Thymosin Beta-4, has been studied in multiple human clinical trials for wound healing and cardiac repair. RegeneRx Biopharmaceuticals ran these trials through Phase 2 before pausing development. TB-500 is the synthetic version used in compounded peptide therapy.Read article , Epitalon Read nextIs Epitalon FDA Approved? 2026 Legal StatusNo. Epitalon has never been tested in Western clinical trials. Its entire evidence base comes from four decades of research at one Russian institute by one scientist: Vladimir Khavinson. That research reported telomerase activation in cultured human cells, a result that has never been independently replicated. Here is why Epitalon never entered the FDA drug-approval pipeline, where it sits in the July 2026 compounding review, and what the Russian data actually shows.Read article , DSIP Read nextIs DSIP FDA Approved? 500 Studies, No US TrialNo. DSIP has never entered clinical trials, never been submitted for FDA approval, and remains one of the strangest molecules in neuroscience. Over 500 studies published. No gene ever found. No receptor identified. No pharmaceutical sponsor. And yet it is one of the most effective sleep peptides in clinical use. Here is why the regulatory gap exists.Read article , AOD-9604 Read nextIs AOD-9604 FDA Approved? 2026 Legal StatusNo, but AOD 9604 has a more extensive clinical trial history than most compounded peptides. It completed Phase 2 clinical trials in Australia for obesity, enrolling over 300 patients. Australia's Therapeutic Goods Administration (TGA) classified it as safe. The development program was discontinued for efficacy reasons at the Phase 2 dose, not safety concerns.Read article , and Thymosin Alpha-1 Read nextIs Thymosin Alpha-1 FDA Approved? Not in the USNot in the United States. But Thymosin Alpha-1 is approved for medical use in over 35 countries under the brand name Zadaxin, primarily for hepatitis B and C treatment and as an immune system modulator. It has FDA Orphan Drug designation for hepatocellular carcinoma. It is one of the most clinically validated peptides in existence, everywhere except the US.Read article , which has the added wrinkle of being an approved drug in dozens of other countries but not the US. Each guide covers that peptide's specific history rather than the general framework laid out here.

Why do promising peptides stay unapproved for decades? Mostly economics. FDA approval requires someone to fund the trial program, and companies fund trials to earn patent-protected exclusivity. Many therapy peptides are older molecules that are difficult to patent, so no sponsor steps forward, and no trials means no NDA regardless of how interesting the early research looks. The absence of approval is often the absence of a business case, not a verdict on the science. That said, it also means the human evidence base for most compounded peptides is genuinely thin, which is exactly why they belong under a licensed provider rather than a gray-market checkout page.

Where Prescription Peptide Therapy Fits

PeRx operates entirely inside lane two. Every peptide we offer is prescribed by a licensed provider after a medical evaluation and prepared by a US-based, state-licensed 503A compounding pharmacy under a patient-specific prescription. None of it is FDA-approved, and we say so plainly, because the compounded lane stands on its own terms: a real prescription, a real pharmacy, purity and potency testing you can request, and a regulated chain of custody from compounding bench to your door. That is the difference between a compounded medication and a "research chemical" with the same name.

The distinction matters most with the GLP-1s, because both lanes carry the same molecule names. Compounded semaglutide and compounded tirzepatide from PeRx contain the same active molecules as the branded drugs, but they are not Ozempic, Wegovy, Mounjaro, or Zepbound, and they are not FDA-approved products. The clinical trials behind the branded approvals were run on the branded formulations. A compounded version is a different product prepared under different rules, and choosing between them is a conversation for you and a licensed provider, with cost, availability, and your medical picture all on the table.

The same honesty applies across the rest of the catalog. BPC-157 is not FDA-approved and we will not tell you otherwise; what we will tell you is that the version a licensed pharmacy compounds under a prescription is a fundamentally different proposition from the version a research-chemical site ships in unmarked vials. Regulatory status is one input. Sourcing, testing, and medical supervision are the ones you can actually control.

FDA-Approved Peptides: Common Questions